BRPI0510394A - inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 - Google Patents
inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1Info
- Publication number
- BRPI0510394A BRPI0510394A BRPI0510394-0A BRPI0510394A BRPI0510394A BR PI0510394 A BRPI0510394 A BR PI0510394A BR PI0510394 A BRPI0510394 A BR PI0510394A BR PI0510394 A BRPI0510394 A BR PI0510394A
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxysteroid dehydrogenase
- inhibitors
- beta
- compounds
- dehydrogenase type
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 title 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 title 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
INIBIDORES DE 11-BETA-HIDROXIESTERóIDE DESIDROGENASE TIPO 1. A presente invenção refere-se a compostos com as fórmula (I), (II), (III) ou (IV): em que R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 7¬, X e Z são como aqui definido, e também à composições farmacêuticas que compreendem os compostos, bem como métodos de uso dos compostos para tratamento de distúrbios associados com a enzima 11-<225>- hidroxiesteróide desidrogenase humana tipo 1 e para a preparação de um medicamento que age sobre a enzima 11-<225>-hidroxiesteróide desidrogenase humana tipo 1.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0401324A SE0401324D0 (sv) | 2004-05-24 | 2004-05-24 | New compounds |
SE0402509A SE0402509D0 (sv) | 2004-10-15 | 2004-10-15 | New compounds |
US65077705P | 2005-01-31 | 2005-01-31 | |
PCT/US2005/018081 WO2005116002A2 (en) | 2004-05-24 | 2005-05-24 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0510394A true BRPI0510394A (pt) | 2007-11-13 |
Family
ID=35134299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0510394-0A BRPI0510394A (pt) | 2004-05-24 | 2005-05-24 | inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 |
Country Status (16)
Country | Link |
---|---|
US (4) | US20070281938A1 (pt) |
EP (1) | EP1753736B1 (pt) |
JP (1) | JP4789934B2 (pt) |
CN (1) | CN1964956B (pt) |
AR (1) | AR049344A1 (pt) |
AT (1) | ATE417837T1 (pt) |
AU (1) | AU2005247929B2 (pt) |
BR (1) | BRPI0510394A (pt) |
CA (1) | CA2568186C (pt) |
DE (1) | DE602005011795D1 (pt) |
EA (1) | EA014419B1 (pt) |
ES (1) | ES2318503T3 (pt) |
GE (1) | GEP20094666B (pt) |
MY (1) | MY148480A (pt) |
TW (1) | TWI352700B (pt) |
WO (1) | WO2005116002A2 (pt) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754709B2 (en) * | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US8686011B2 (en) | 2004-05-24 | 2014-04-01 | Amgen Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
WO2005116002A2 (en) * | 2004-05-24 | 2005-12-08 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
WO2006074330A2 (en) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
BRPI0606256A2 (pt) | 2005-01-05 | 2009-06-09 | Abbott Lab | inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
US7563813B2 (en) * | 2005-05-13 | 2009-07-21 | Wyeth | Iminothiazolidinone derivatives as SFRP-1 antagonists |
EP1902051A1 (en) * | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US8541592B2 (en) | 2005-11-22 | 2013-09-24 | Amgen Inc. | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 |
EP1951695B1 (en) | 2005-11-22 | 2009-12-23 | Amgen Inc. | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 |
AU2007207055B2 (en) | 2006-01-18 | 2011-06-02 | F. Hoffmann-La Roche Ag | Thiazoles as 11 beta-HSD1 inhibitors |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US9090604B2 (en) | 2006-07-27 | 2015-07-28 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US8927715B2 (en) | 2006-08-25 | 2015-01-06 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
WO2008061160A1 (en) * | 2006-11-14 | 2008-05-22 | Pharmacyclics, Inc. | Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions |
WO2008090356A1 (en) * | 2007-01-25 | 2008-07-31 | Betagenon Ab | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity |
JP5615700B2 (ja) | 2007-05-25 | 2014-10-29 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 代謝型グルタミン酸受容体2(mglu2受容体)の陽性調節剤としての複素環化合物 |
US8765788B2 (en) | 2007-06-14 | 2014-07-01 | Amgen Inc. | Tricyclic inhibitors of hydroxysteroid dehydrogenases |
MX2009013869A (es) * | 2007-06-21 | 2010-03-17 | Amgen Inc | Proceso para hacer 2-amino-tiazolonas sustituidas. |
ES2395081T3 (es) | 2007-07-26 | 2013-02-08 | Vitae Pharmaceuticals, Inc. | Síntesis de inhibidores de la 11beta-hidroxiesteroide deshidrogenasa de tipo 1 |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
EP2208728A4 (en) * | 2007-09-19 | 2011-12-21 | Inst Med Molecular Design Inc | HETEROCYCLIC DERIVATIVE DERIVATIVE DERIVATIVE TO 11 -? - HYDROXYSTEROIDDEHYDROGENASE TYPE I |
AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
EP2252601B1 (en) | 2008-01-24 | 2012-12-19 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2009102460A2 (en) | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
ES2421537T3 (es) | 2008-05-01 | 2013-09-03 | Vitae Pharmaceuticals Inc | Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 |
JP5538365B2 (ja) | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
CA2727674A1 (en) * | 2008-06-20 | 2010-01-21 | Amgen Inc. | Process for making substituted 2-amino-thiazolones |
JP5777030B2 (ja) | 2008-07-25 | 2015-09-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤 |
PL2324018T3 (pl) | 2008-07-25 | 2014-02-28 | Boehringer Ingelheim Int | Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1 |
EP2323994A1 (en) | 2008-07-25 | 2011-05-25 | Boehringer Ingelheim International GmbH | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
JP2011529896A (ja) | 2008-07-29 | 2011-12-15 | アムジェン インコーポレイテッド | 置換2−アミノ−チアゾロンの合成のための不斉プロセス |
WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
EP2393807B1 (en) | 2009-02-04 | 2013-08-14 | Boehringer Ingelheim International GmbH | Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1 |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
JP5656986B2 (ja) | 2009-06-11 | 2015-01-21 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 1,3−オキサジナン−2−オン構造に基づく11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
US8552212B2 (en) | 2009-11-05 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Chiral phosphorus ligands |
JP2013531636A (ja) | 2010-05-26 | 2013-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 2−オキソ−1,2−ジヒドロピリジン−4−イルボロン酸誘導体 |
EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン |
MX2013003344A (es) | 2010-09-23 | 2013-06-28 | Abbvie Inc | Monohidrato de un derivado de azaadamantano. |
WO2012051139A1 (en) | 2010-10-15 | 2012-04-19 | Amgen Inc. | New uses for substituted 2-amino-thiazolones in treating alzheimer's disease |
CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
CN102408392A (zh) * | 2011-11-10 | 2012-04-11 | 浙江大学 | 水相中2-(n, n-二取代氨基)-4-噻唑啉酮的绿色制备方法 |
RU2483722C1 (ru) * | 2012-05-22 | 2013-06-10 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Аминотиазольные производные усниновой кислоты как новые противотуберкулезные агенты |
AU2015362790A1 (en) | 2014-12-16 | 2017-07-20 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
RU2017145964A (ru) | 2015-06-10 | 2019-07-10 | Аксовант Сайенсиз Гмбх | Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов |
WO2017027600A1 (en) | 2015-08-12 | 2017-02-16 | Forum Pharmaceuticals, Inc. | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS |
CN115322208B (zh) * | 2021-05-10 | 2023-04-11 | 中国药科大学 | 2-氨基噻唑类衍生物及其制备方法和医药用途 |
CN115010616B (zh) * | 2022-07-01 | 2024-03-26 | 常州锐博生物科技有限公司 | 一种1-氨基环丙烷羧酸盐酸盐的合成方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2786838A (en) * | 1957-03-26 | Cshy b | ||
US2701248A (en) * | 1950-12-30 | 1955-02-01 | Monsanto Chemicals | Esters of pseudothiohydantoin-5-acetic acid and method for their preparation |
DE929549C (de) * | 1951-11-29 | 1955-08-01 | Hoechst Ag | Verfahren zur Herstellung substituierter Pseudothiohydantoine und ihrer Hydrohalogenide |
FR6278M (pt) * | 1966-12-14 | 1968-09-02 | ||
US4428948A (en) * | 1977-02-03 | 1984-01-31 | Rohm And Haas Company | Novel heterocyclic compounds |
JPS58183603A (ja) * | 1982-04-19 | 1983-10-26 | Mitsubishi Chem Ind Ltd | 土壌病害用殺菌剤 |
ZA844557B (en) * | 1983-06-23 | 1985-02-27 | Hoffmann La Roche | Novel thiazolidine derivatives |
DK277484A (da) * | 1983-06-23 | 1984-12-24 | Hoffmann La Roche | Thiazolidinderivater |
JPH08277266A (ja) * | 1983-09-14 | 1996-10-22 | Alcon Lab | スピロ三環式芳香族スクシンイミド誘導体、並びにヒト及び動物の糖尿病合併症治療剤 |
JPS6360987A (ja) * | 1986-08-29 | 1988-03-17 | Tanabe Seiyaku Co Ltd | キナゾリノン誘導体の製法 |
MY116093A (en) * | 1996-02-26 | 2003-11-28 | Upjohn Co | Azolyl piperazinyl phenyl oxazolidinone antimicrobials |
KR20000005291A (ko) * | 1996-06-25 | 2000-01-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 옥사졸론 유도체 및 항-헬리코박터 파일로리 제제로서의 이의용도 |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
AU2002353717B2 (en) | 2001-11-22 | 2006-08-03 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
ATE469136T1 (de) * | 2001-11-22 | 2010-06-15 | Biovitrum Ab | Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1 |
MXPA04004837A (es) | 2001-11-22 | 2004-08-02 | Biovitrum Ab | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. |
AR037714A1 (es) * | 2001-12-06 | 2004-12-01 | Maxia Pharmaceuticals Inc | Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer |
EP1631558A1 (en) | 2003-05-21 | 2006-03-08 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
US7173030B2 (en) | 2003-05-21 | 2007-02-06 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
SE0301888D0 (sv) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
SE0301882D0 (sv) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
SE0301883D0 (sv) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use II |
WO2004113310A1 (en) | 2003-06-25 | 2004-12-29 | Biovitrum Ab | Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing |
SE0301884D0 (sv) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use III |
SE0301886D0 (sv) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use V |
SE0301885D0 (sv) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use IV |
US20050239853A1 (en) * | 2004-02-04 | 2005-10-27 | Tjeerd Barf | New compounds |
WO2005116002A2 (en) * | 2004-05-24 | 2005-12-08 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
-
2005
- 2005-05-24 WO PCT/US2005/018081 patent/WO2005116002A2/en active Application Filing
- 2005-05-24 DE DE602005011795T patent/DE602005011795D1/de active Active
- 2005-05-24 AT AT05756354T patent/ATE417837T1/de not_active IP Right Cessation
- 2005-05-24 EA EA200602191A patent/EA014419B1/ru not_active IP Right Cessation
- 2005-05-24 BR BRPI0510394-0A patent/BRPI0510394A/pt not_active IP Right Cessation
- 2005-05-24 JP JP2007515235A patent/JP4789934B2/ja not_active Expired - Fee Related
- 2005-05-24 EP EP05756354A patent/EP1753736B1/en active Active
- 2005-05-24 MY MYPI20052347A patent/MY148480A/en unknown
- 2005-05-24 US US11/596,982 patent/US20070281938A1/en not_active Abandoned
- 2005-05-24 AR ARP050102153A patent/AR049344A1/es not_active Application Discontinuation
- 2005-05-24 TW TW094116862A patent/TWI352700B/zh not_active IP Right Cessation
- 2005-05-24 AU AU2005247929A patent/AU2005247929B2/en not_active Ceased
- 2005-05-24 CN CN2005800166858A patent/CN1964956B/zh not_active Expired - Fee Related
- 2005-05-24 GE GEAP20059780A patent/GEP20094666B/en unknown
- 2005-05-24 ES ES05756354T patent/ES2318503T3/es active Active
- 2005-05-24 CA CA2568186A patent/CA2568186C/en not_active Expired - Fee Related
- 2005-05-24 US US11/135,662 patent/US7253196B2/en not_active Expired - Fee Related
-
2007
- 2007-06-28 US US11/819,607 patent/US7807700B2/en not_active Expired - Fee Related
-
2010
- 2010-10-05 US US12/898,279 patent/US20110082107A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2005247929A1 (en) | 2005-12-08 |
US20080045503A1 (en) | 2008-02-21 |
TWI352700B (en) | 2011-11-21 |
MY148480A (en) | 2013-04-30 |
AU2005247929B2 (en) | 2010-03-11 |
EA200602191A1 (ru) | 2007-06-29 |
GEP20094666B (en) | 2009-04-10 |
US20070281938A1 (en) | 2007-12-06 |
CA2568186A1 (en) | 2005-12-08 |
TW200609227A (en) | 2006-03-16 |
CN1964956B (zh) | 2013-03-27 |
ATE417837T1 (de) | 2009-01-15 |
EP1753736A2 (en) | 2007-02-21 |
WO2005116002A3 (en) | 2006-07-06 |
WO2005116002A2 (en) | 2005-12-08 |
CN1964956A (zh) | 2007-05-16 |
EP1753736B1 (en) | 2008-12-17 |
CA2568186C (en) | 2011-11-15 |
AR049344A1 (es) | 2006-07-19 |
US20060142357A1 (en) | 2006-06-29 |
JP4789934B2 (ja) | 2011-10-12 |
US20110082107A1 (en) | 2011-04-07 |
US7253196B2 (en) | 2007-08-07 |
WO2005116002B1 (en) | 2006-08-24 |
JP2008500353A (ja) | 2008-01-10 |
DE602005011795D1 (de) | 2009-01-29 |
EA014419B1 (ru) | 2010-12-30 |
ES2318503T3 (es) | 2009-05-01 |
US7807700B2 (en) | 2010-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510394A (pt) | inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 | |
BRPI0508098A (pt) | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos | |
BR0214342A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
BR0214344A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
ATE469136T1 (de) | Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1 | |
BRPI0511532A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto | |
BRPI0611863A2 (pt) | composto, bem como composiÇço e kit compreendendo o mesmo, composto intermediÁrio na preparaÇço do mesmo, mÉtodo para tratamento e uso do mesmo | |
BR0214386A (pt) | Método para identificação de enzimas de objetivação a tumor | |
BRPI0519148A2 (pt) | inibidores de homodimerizaÇço de myd88 | |
BRPI0415683A (pt) | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central | |
EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
BRPI0514295A (pt) | 1, 5-difenilpirazóis | |
BRPI0813244B8 (pt) | compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário | |
SE0001899D0 (sv) | New compounds | |
BRPI0413695A (pt) | derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas | |
BRPI0518898A2 (pt) | composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto | |
BRPI0512938A (pt) | derivados da quinazolinediona como inibidores parp | |
BRPI0517803A (pt) | pirazolpirimidinas 1,4-substituìdas como inibidores de cinase | |
BRPI0510453A (pt) | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central | |
WO2005075471A3 (en) | Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
BRPI0511531A (pt) | composto, uso de um composto, composição farmacêutica, e, métodos para terapia de distúrbios gastrointestinais funcionais, de sìndrome do intestino irritável e de distúrbio de refluxo gastro-esofágico e para preparar um composto | |
BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2309 DE 07/04/2015. |